Literature DB >> 18843262

Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency.

M J Kennedy1, D A Davis, N Smith, A Gaedigk, R E Pearce, G L Kearns.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18843262      PMCID： PMC2650481          DOI： 10.1038/clpt.2008.185

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  30 in total

1.  Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee.

Authors:  Thomas A Wilson; Susan R Rose; Pinchas Cohen; Alan D Rogol; Philippe Backeljauw; Rosalind Brown; Dana S Hardin; Stephen F Kemp; Margaret Lawson; Sally Radovick; Stephen M Rosenthal; Lawrence Silverman; Phyllis Speiser
Journal:  J Pediatr       Date:  2003-10       Impact factor: 4.406

2.  Pharmacokinetics of theophylline in children with asthma.

Authors:  E F Ellis; R Koysooko; G Levy
Journal:  Pediatrics       Date:  1976-10       Impact factor: 7.124

3.  Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity.

Authors:  G R Matzke; R F Frye; J J Early; R J Straka; S W Carson
Journal:  Pharmacotherapy       Date:  2000-02       Impact factor: 4.705

4.  Changes in drug metabolism in children with thyroid disorders.

Authors:  P Saenger; A B Rifkind; M I New
Journal:  J Clin Endocrinol Metab       Date:  1976-01       Impact factor: 5.958

5.  Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children.

Authors:  Mary Jayne Kennedy; Susan M Abdel-Rahman; Angela D M Kashuba; J Steven Leeder
Journal:  J Clin Pharmacol       Date:  2004-07       Impact factor: 3.126

6.  Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis.

Authors:  Mary Jayne Kennedy; Charity D Scripture; Angela D M Kashuba; Christy S Scott; Andrea Gaedigk; Gregory L Kearns
Journal:  Clin Pharmacol Ther       Date:  2004-03       Impact factor: 6.875

7.  Effect of human growth hormone on amobarbital metabolism in children.

Authors:  G P Redmond; J J Bell; J M Perel
Journal:  Clin Pharmacol Ther       Date:  1978-08       Impact factor: 6.875

8.  Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement.

Authors:  Mary Jayne Kennedy; Daniel A Davis; Ned Smith; Andrea Gaedigk; Robin E Pearce; Gregory L Kearns
Journal:  Clin Ther       Date:  2008-09       Impact factor: 3.393

9.  Effect of growth hormone on human drug metabolism: time course and substrate specificity.

Authors:  G P Redmond; J J Bell; P S Nichola; J M Perel
Journal:  Pediatr Pharmacol (New York)       Date:  1980

10.  Effects of growth hormone on antipyrine kinetics in children.

Authors:  A B Rifkind; P Saenger; L S Levine; J Pareira; M I New
Journal:  Clin Pharmacol Ther       Date:  1981-07       Impact factor: 6.875
View more
  3 in total

1.  Special population considerations and regulatory affairs for clinical research.

Authors:  Kristin N Grimsrud; Catherine M T Sherwin; Jonathan E Constance; Casey Tak; Athena F Zuppa; Michael G Spigarelli; Nicole L Mihalopoulos
Journal:  Clin Res Regul Aff       Date:  2015

Review 2.  Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence.

Authors:  Mj Kennedy
Journal:  Clin Pharmacol Ther       Date:  2008-10-29       Impact factor: 6.875

3.  Results and challenges of Cytochrome P450 2D6 (CYP2D6) testing in an ethnically diverse South Florida population.

Authors:  Daria Salyakina; Sharmeen Roy; Weize Wang; Mailin Oliva; Rohan Akhouri; Ileana Sotto; Nicole Mulas; Rafaela Solano; José R Fernández; Stephanie Sanchez; Uzma Shamshad; Chad Perlyn; Jennifer McCafferty-Fernandez
Journal:  Mol Genet Genomic Med       Date:  2019-08-07       Impact factor: 2.183
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.